Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Accurately determining a company’s long-term prospects isn’t easy, especially when sentiment is weak. That’s where StockStory comes in - to help you find attractive investment candidates backed by unbiased research. That said, here are two stocks where you should be greedy instead of fearful and one where the skepticism is well-placed.
One Stock to Sell:
Rockwell Automation (ROK)
Consensus Price Target: $463.66 (-3.3% implied return)
One of the first companies to address industrial automation, Rockwell Automation (NYSE: ROK) sells products that help customers extract more efficiency from their machinery.
Why Is ROK Not Exciting?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Estimated sales growth of 4.1% for the next 12 months is soft and implies weaker demand
- Waning returns on capital imply its previous profit engines are losing steam
Rockwell Automation’s stock price of $479.36 implies a valuation ratio of 34.6x forward P/E. Dive into our free research report to see why there are better opportunities than ROK.
Two Stocks to Watch:
Champion Homes (SKY)
Consensus Price Target: $90.67 (12.6% implied return)
Founded in 1951, Champion Homes (NYSE: SKY) is a manufacturer of modular homes and buildings in North America.
Why Does SKY Stand Out?
- Impressive 14.7% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 20.4% exceeded its revenue gains over the last five years
- ROIC punches in at 38%, illustrating management’s expertise in identifying profitable investments
Champion Homes is trading at $80.55 per share, or 24.5x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Hims & Hers Health (HIMS)
Consensus Price Target: $26.61 (-20.1% implied return)
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE: HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Do We Love HIMS?
- Business is winning new contracts that can potentially increase in value as its customer base averaged 26.1% growth over the past two years
- Free cash flow margin increased by 16.1 percentage points over the last five years, giving the company more capital to invest or return to shareholders
- Improving returns on capital suggest its past investments are beginning to deliver value
At $33.30 per share, Hims & Hers Health trades at 2.7x forward price-to-sales. Is now a good time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
